Printer Friendly

CYTOTHERAPEUTICS NAMES E. EDWARD BAETGE DIRECTOR OF NEUROSCIENCE

 CYTOTHERAPEUTICS NAMES E. EDWARD BAETGE DIRECTOR OF NEUROSCIENCE
 PROVIDENCE, R.I., June 11 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) announced today the appointment of E. Edward Baetge, Ph.D., as director of neuroscience. Baetge joins CytoTherapeutics from Bristol-Myers Squibb Co., where he most recently served as group leader: Cell and Molecular Neurobiology Group.
 "Dr. Baetge's proven leadership abilities and technical accomplishments will add significantly to our scientific team." said Seth A. Rudnick, M.D., CytoTherapeutics' president and CEO. "His expertise in neurology will strengthen our NeuroCrib(tm) product development program for the treatment of Parkinson's disease. We are excited to welcome him to the company."
 Baetge held several positions at Bristol-Myers Squibb including senior research investigator and research scientist. Prior to Bristol- Myers Squibb Baetge served as associate research scientist at the Howard Hughes Medical Institute in Seattle. Baetge's research focus is the study of cellular and molecular processes related to the chronic degeneration of the nervous system with a major emphasis on Alzheimer's Disease.
 Baetge holds a Ph.D. degree in molecular neurobiology from Cornell University Medical College and a B.A. degree in biology from University of California at San Diego.
 CytoTherapeutics is a leader in the research and development of a novel approach to cell therapy for the treatment of severe, chronic disease. The company is developing a new class of therapeutic products based on its core technology of membrane-encapsulated living cells which can be safely implanted in patients where they supply biomolecules critical to treat disease. The company's product development efforts are concentrated in three areas: NeuroCRIB for treatment of Parkinson's disease; EndoCRIB(tm) for the treatment of Type I diabetes, and CereCRIB(tm) for the treatment of chronic pain.
 -0- 6/11/92
 /CONTACT: Elizabeth Razee of Cytotherapeutics, 401-272-3310 x132, or Jeanine Kelly of Feinstein Partners, 617-577-8110, for CytoTherapeutics/
 (CTII) CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU: PER


TM -- NE001 -- 9143 06/11/92 09:57 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 11, 1992
Words:323
Previous Article:CONSUMERS POWER ELECTRIC CONSERVATION PROGRAM REDUCES CUSTOMER'S USE
Next Article:FORTIS AND N.V. AMEV REPORT FIRST QUARTER RESULTS
Topics:


Related Articles
WASHINGTON U. RESEARCHERS, CYTOTHERAPEUTICS REPORT DIABETES RESEARCH ADVANCE IN SCIENCE; ISLET CELL IMPLANTS UNDER SKIN CONTROL GLUCOSE LEVEL
CYTOTHERAPEUTICS ANNOUNCES INITIAL PUBLIC OFFERING OF 2.25 MILLION SHARES OF COMMON STOCK AT $11 PER SHARE
CYTOTHERAPEUTICS ANNOUNCES THIRD QUARTER RESULTS
CYTOTHERAPEUTICS ANNOUNCES BROAD U.S. PATENT COVERING THE USE OF MULTIPLE CELL TYPES IN THERAPEUTIC IMPLANTS
CYTOTHERAPEUTICS' DEMONSTRATES FIRST DELIVERY OF HUMAN NERVE GROWTH FACTOR VIA ENCAPSULATED XENOGENEIC CELL IN PRIMATE MODEL OF ALZHEIMER'S
CYTOTHERAPEUTICS REPORTS SCIENTIFIC PROGRESS IN PROGRAM TO DELIVER NERVE GROWTH FACTOR (NGF) TO THE BRAIN
CYTOTHERAPEUTICS FILES REGISTRATION STATEMENT FOR OFFERING OF 400,000 UNITS
CYTOTHERAPEUTICS FILES REGISTRATION STATEMENT FOR OFFERING OF 1.5 MILLION SHARES OF COMMON STOCK
NATURE MEDICINE PUBLISHES INITIAL CLINICAL DATA ON CYTOTHERAPEUTICS' DELIVERY SYSTEM FOR GROWTH FACTORS
CytoTherapeutics acquires stem cell product pipeline

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters